Separately, Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday.
Check Out Our Latest Analysis on Supernus Pharmaceuticals
SUPN stock traded down $0.15 on Thursday, hitting $31.76. 705,876 shares of the company were exchanged, compared to its average volume of 490,836. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of 29.68 and a beta of 0.90. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28. The business's fifty day moving average is $37.19 and its two-hundred day moving average is $35.34.
In other news, VP Padmanabh P. Bhatt sold 700 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 over the last quarter. Corporate insiders own 9.30% of the company's stock.
A number of hedge funds have recently modified their holdings of SUPN. Pacer Advisors Inc. boosted its position in shares of Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company's stock valued at $54,655,000 after purchasing an additional 403,028 shares during the period. Woodline Partners LP lifted its stake in Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after buying an additional 235,257 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after buying an additional 208,552 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $6,847,000. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $6,131,000.
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.